Needham & Company LLC Reaffirms “Buy” Rating for CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating reissued by Needham & Company LLC in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $80.00 price target on the stock. Needham & Company LLC’s price objective indicates a potential upside of 40.62% from the stock’s current price.

A number of other equities research analysts have also recently commented on CRSP. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, September 23rd. Citigroup restated a “buy” rating and set a $77.00 target price (down previously from $87.00) on shares of CRISPR Therapeutics in a research note on Tuesday, November 11th. Zacks Research raised shares of CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. Finally, Royal Bank Of Canada raised their price target on CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a report on Tuesday, November 11th. Twelve analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and an average price target of $68.35.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $56.89 on Tuesday. The stock has a market cap of $5.42 billion, a P/E ratio of -10.18 and a beta of 1.74. The stock’s fifty day moving average is $57.80 and its 200 day moving average is $57.07. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, November 10th. The company reported ($1.17) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.15. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%.The business had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $8.74 million. Analysts predict that CRISPR Therapeutics will post -5.16 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 50,895 shares of CRISPR Therapeutics stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $67.91, for a total value of $3,456,279.45. Following the sale, the chief executive officer directly owned 254,201 shares of the company’s stock, valued at approximately $17,262,789.91. The trade was a 16.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 1,076 shares of the business’s stock in a transaction dated Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total value of $71,661.60. Following the completion of the sale, the general counsel owned 83,402 shares in the company, valued at $5,554,573.20. This represents a 1.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 56,213 shares of company stock worth $3,810,458. 4.30% of the stock is currently owned by insiders.

Institutional Trading of CRISPR Therapeutics

A number of large investors have recently added to or reduced their stakes in CRSP. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of CRISPR Therapeutics by 5.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company’s stock valued at $228,000 after acquiring an additional 180 shares during the last quarter. IFP Advisors Inc raised its stake in CRISPR Therapeutics by 24.6% during the second quarter. IFP Advisors Inc now owns 916 shares of the company’s stock valued at $45,000 after purchasing an additional 181 shares in the last quarter. Cerity Partners LLC lifted its position in CRISPR Therapeutics by 3.0% during the second quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock valued at $318,000 after purchasing an additional 190 shares during the last quarter. Peapack Gladstone Financial Corp grew its stake in shares of CRISPR Therapeutics by 3.0% in the 2nd quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock worth $339,000 after buying an additional 200 shares in the last quarter. Finally, Optiver Holding B.V. increased its holdings in shares of CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after buying an additional 210 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Key Stores Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Early zugo‑cel clinical data showed sustained B‑cell depletion and early efficacy across autoimmune and cancer studies, which traders read as a strong validation of CRSP’s pipeline and lifted the stock. How Early Zugo‑cel Data and Lilly Partnership Could Impact CRISPR Therapeutics CRSP Stock Rises on Encouraging Early Data From Zugo‑cel Studies
• Positive Sentiment: Analyst support strengthened the tape: Citizens/JMP reiterated a market‑outperform and Needham reaffirmed a buy, both with high price targets (mid‑$80s to $80), giving implied upside vs. current levels. Citizens Reiterates Market Outperform Analyst Price Target Coverage
• Positive Sentiment: Technical momentum: CRSP cleared a key benchmark and reached an 80+ relative‑strength rating, a signal some momentum traders use to add exposure. RS Rating Coverage
• Neutral Sentiment: Longer‑term thesis debate: a Fool.com piece questions whether CRISPR is “yesterday’s news,” noting the stock’s fall from prior highs and highlighting the challenge of scaling commercial execution after early approvals. This is more thematic commentary than immediate catalyst. Is CRISPR Therapeutics Stock Yesterday’s News?
• Neutral Sentiment: Short‑interest report appears erroneous or inconclusive (entries show “0 shares” and NaN increases); there’s no clear short‑squeeze signal from the published data. Investors should treat this item with caution.
• Negative Sentiment: Market‑wide weakness pressured the stock in the prior session — a Zacks note flagged a ~2.5% intraday decline, indicating CRSP is still sensitive to broader biotech/market flows despite company‑specific positives. CRSP Stock Falls Amid Market Uptick

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.